ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
New York, NY, Dec. 28, 2017 -- Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, revises the record date and payment date of its 2017 dividend. The Board of Directors has reaffirmed the annual dividend payment of $0.03 per share. This dividend will be paid on Friday, January 12, 2018 to Daxor shareholders of record on Monday January 8, 2018. The change in dates is procedural to comply with regulatory reporting requirements.
Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor’s single-use diagnostic kit. For more information regarding blood volume analysis and the Daxor BVA-100, visit Daxor’s website at www.Daxor.com.
Daxor contact information: Michael Feldschuh, President and CEO, 212-330-8505, [email protected] John Wilkens, Chief Financial Officer, 212-330-8504, [email protected].
